Simulations Plus to Present at the 21st Annual Needham Growth Conference
Thursday, 10 January 2019 04:06
Jan. 10, 2019 13:30 UTC

Simulations Plus to Present at the 21st Annual Needham Growth Conference

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq:SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 21st Annual Needham Growth Conference in New York City on Wednesday, January 16, 2019, at 8:40 a.m. ET (5:40 a.m. PT). In addition to his presentation, Mr. O’Connor will host one-on-one meetings throughout the day at the conference which will be held at the Lotte New York Palace Hotel.

A live webcast of the presentation will be accessible from the Events section of the Company's website ( The webcast will be archived for a period of 90 days. For more information about the conference or to schedule a one-on-one meeting with Mr. O’Connor, please contact Hayden IR at [email protected].

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury, drug-induced kidney injury, and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at

Follow us on Twitter | LinkedIn


Simulations Plus Investor Relations
Ms. Renee Bouche
[email protected]

Hayden IR
Mr. Cameron Donahue
[email protected]

Source: Simulations Plus, Inc.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!